Published in Clinical Trials Week, January 25th, 2010
CEL-SCI reported an operating loss for fiscal year 2009 of $ (12,100,550) versus an operating loss of $ (9,517,358) in fiscal year 2008. Included in this operating loss in 2009 were non-cash expenditures that added up to approximately $5.5 million. In addition, CEL-SCI also incurred a $28.5 million non-cash loss related to derivative accounting. This loss was primarily a result of the significant increase in the Company's share price. CEL-SCI expects to report a substantial gain related to derivative accounting in the quarter ending December 31, 2009.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Trials Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.